Navigation Links
Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
Date:10/14/2010

FRAZER, Pa., Oct. 14 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that a Risk Evaluation and Mitigation Strategy (REMS) for its antiepileptic medication GABITRIL(R) (tiagabine hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA).  The GABITRIL REMS consists of a Medication Guide to inform patients about the potential risks associated with the use of GABITRIL.  The implementation of the REMS is a result of FDA's identification in 2008 of an increased risk of suicidal thoughts and behavior with the class of antiepileptic drugs (AEDs) which includes GABITRIL.  The current product labeling already contains a warning that includes this risk.  The addition of a Medication Guide for patients and ongoing assessment of the REMS program is consistent with the company's commitment to safe and appropriate use of its medications.  

The GABITRIL Medication Guide will be available on the product website, www.gabitril.com, and will be dispensed with every prescription.  The three-pronged REMS assessment plan will be implemented on an ongoing basis to evaluate (1) patients' understanding of the potential serious risks associated with the medication; (2) the distribution and dispensing of the Medication Guide; and (3) adherence to distribution and dispensing requirements as well as corrective actions taken to address noncompliance.  In accordance with the approved REMS, the company is currently updating all labeling related to GABITRIL to include the Medication Guide.

Additional information on GABITRIL is available at www.GABITRIL.com or at 1-800-896-5855.  More information on Cephalon and its products is available at www.cephalon.com.  

About GABITRILGABITRIL is indicated as an adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures.  

Important Safety Information Postmarketing reports have shown that GABITRIL use has been associated with new onset seizures and status epilepticus in patients without epilepsy.  Safety and effectiveness of GABITRIL have not been established for any indication other than as adjunctive therapy for partial seizures.  In nonepileptic patients who develop seizures while on GABITRIL treatment, GABITRIL should be discontinued and patients should be evaluated for an underlying seizure disorder. Antiepileptic drugs (AEDs), including GABITRIL, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

GABITRIL should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.  In clinical trials, the most common adverse events for GABITRIL in combination with other anticonvulsants were dizziness/lightheadedness, asthenia/lack of energy, somnolence, nausea, nervousness/irritability, tremor, abdominal pain, and thinking abnormal/difficulty with concentration or attention.

About Cephalon, Inc.Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world.  Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas.  Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide.  The company sells numerous branded and generic products around the world.  In total, Cephalon sells more than 150 products in nearly 100 countries. More information on Cephalon and its products is available at www.cephalon.com.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide the Cephalon current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.Contacts:Media: Investor Relations:Candace Steele Flippin

Robert (Chip) Merritt610-727-6231 (office)

610-738-6376 (office) csteele@cephalon.com

cmerritt@cephalon.comJoseph Marczely610-883-5894jmarczely@cephalon.com
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... 2017  US medical equipment and supply demand is ... Medical Equipment & Supplies: United States ... Continued increases in demand for medical services – driven ... and supported by gains in disposable personal income – ... product introductions will also drive sales as providers and ...
(Date:7/10/2017)... RESEARCH TRIANGLE PARK, N.C. , July 10, 2017 ... of a $5m Convertible Note to support the development ... led by Tencent Holdings Limited, a leading Chinese Internet ... Center. This funding will advance multiple infectious disease product ... Founded by Dr. ...
(Date:7/5/2017)... , July 5, 2017 Pace Analytical, a company of over ... today that they have acquired ESC Lab Sciences, further solidifying their position as ... United States . ... Steve Vanderboom- President and CEO of Pace Analytical ... ESC Lab Sciences out of Mt Juliet, TN , enhances ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended hospital stays ... beds used in such facilities are specially designed to accommodate patients with a wide ... , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM REST, a ...
(Date:7/20/2017)... ... July 20, 2017 , ... Girl ... bipartisan House and Senate legislation in support of providing girls access to education ... introduced H.R. 2408, the “Protecting Girls’ Access to Education in Vulnerable Settings Act.” ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... Business Architecture Body of Knowledge (BIZBOK® Guide )v 6.0 is now available for ... this effort through Guild collaborative teams. , Non-members may download the Part ...
(Date:7/20/2017)... ... ... Dr. Jig Patel is pleased to announce openings for new patients who ... the difficulties that face people who are missing teeth , he offers education ... dentures and bridges. Not only does an implant improve oral health, it also restores ...
(Date:7/20/2017)... ... July 19, 2017 , ... A July 5th article on ... patients who had received a body contouring procedure reported experiencing a better quality of ... Physicians (BHP), which provides both types of procedures, notes that this report jibes with ...
Breaking Medicine News(10 mins):